These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 7853186)

  • 41. Pseudoperoxidase activity of 5-lipoxygenase stimulated by potent benzofuranol and N-hydroxyurea inhibitors of the lipoxygenase reaction.
    Riendeau D; Falgueyret JP; Guay J; Ueda N; Yamamoto S
    Biochem J; 1991 Feb; 274 ( Pt 1)(Pt 1):287-92. PubMed ID: 2001245
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis.
    Weinblatt ME; Kremer JM; Coblyn JS; Helfgott S; Maier AL; Petrillo G; Henson B; Rubin P; Sperling R
    J Rheumatol; 1992 Oct; 19(10):1537-41. PubMed ID: 1334515
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.
    Li L; Ji H; Sheng L; Zhang Y; Lai Y; Chen X
    Eur J Pharmacol; 2009 Apr; 607(1-3):244-50. PubMed ID: 19243697
    [TBL] [Abstract][Full Text] [Related]  

  • 44. In vitro effect of N-methoxy-3-(3,5-ditert-butyl-4-hydroxybenzylidene)-2-pyrrolidon e (E-5110), a novel nonsteroidal antiinflammatory agent, on generation of some inflammatory mediators.
    Katayama K; Shirota H; Kobayashi S; Terato K; Ikuta H; Yamatsu I
    Agents Actions; 1987 Aug; 21(3-4):269-71. PubMed ID: 2825479
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
    Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich P; Darlington JV; Hutchinson JH; King C; Lee C; Baccei C; Li Y; Arruda JM; Evans JF
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1042-50. PubMed ID: 19749079
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of leukotriene B4 synthesis does not prevent development of acute renal failure following storage and transplantation.
    Lane NJ; Thorniley MS; Manek S; Fuller BJ; Green CJ
    Transplantation; 1994 Dec; 58(12):1303-8. PubMed ID: 7809921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Leukotriene B4 production by the human alveolar macrophage: a potential mechanism for amplifying inflammation in the lung.
    Martin TR; Altman LC; Albert RK; Henderson WR
    Am Rev Respir Dis; 1984 Jan; 129(1):106-11. PubMed ID: 6322626
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of arachidonic acid 5-lipoxygenase of human polymorphonuclear leukocytes by esculetin.
    Panossian AG
    Biomed Biochim Acta; 1984; 43(12):1351-5. PubMed ID: 6100067
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics.
    Müller-Peddinghaus R; Fruchtmann R; Ahr HJ; Beckermann B; Bühner K; Fugmann B; Junge B; Matzke M; Kohlsdorfer C; Raddatz S
    J Lipid Mediat; 1993; 6(1-3):245-8. PubMed ID: 8395246
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of ABT-761, a novel 5-lipoxygenase inhibitor, on exercise- and adenosine-induced bronchoconstriction in asthmatic subjects.
    Van Schoor J; Joos GF; Kips JC; Drajesk JF; Carpentier PJ; Pauwels RA
    Am J Respir Crit Care Med; 1997 Mar; 155(3):875-80. PubMed ID: 9117020
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effects of phosphodiesterase type 4 inhibitors on tumour necrosis factor-alpha and leukotriene B4 in a novel human whole blood assay.
    Brideau C; Van Staden C; Styhler A; Rodger IW; Chan CC
    Br J Pharmacol; 1999 Feb; 126(4):979-88. PubMed ID: 10193778
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Selective chiral inhibitors of 5-lipoxygenase with anti-inflammatory activity.
    McMillan RM; Girodeau JM; Foster SJ
    Br J Pharmacol; 1990 Nov; 101(3):501-3. PubMed ID: 1963796
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Use of a continuous assay of oxygen consumption to evaluate the pharmacology of 5-lipoxygenase inhibitors.
    Breton J; Keller P; Chabot-Fletcher M; Hillegass L; DeWolf W; Griswold D
    Prostaglandins Leukot Essent Fatty Acids; 1993 Dec; 49(6):929-37. PubMed ID: 8140120
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chiral dioxolane inhibitors of leukotriene biosynthesis: structure-activity relationships and syntheses using asymmetric dihydroxylation.
    Crawley GC; Briggs MT
    J Med Chem; 1995 Sep; 38(20):3951-6. PubMed ID: 7562928
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Studies on 5-lipoxygenase inhibitors. II. Discovery, optical resolution and enantioselective synthesis of FR110302, a highly potent non-redox type 5-lipoxygenase inhibitor.
    Yatabe T; Kayakiri H; Kawai Y; Oku T; Tanaka H
    Chem Pharm Bull (Tokyo); 1998 Oct; 46(10):1556-65. PubMed ID: 9810693
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Benzothiazole hydroxy ureas as inhibitors of 5-lipoxygenase: use of the hydroxyurea moiety as a replacement for hydroxamic acid.
    Greco MN; Hageman WE; Powell ET; Tighe JJ; Persico FJ
    J Med Chem; 1992 Aug; 35(17):3180-3. PubMed ID: 1324317
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Drug interactions with zileuton.
    Lau R
    Lancet; 1997 May; 349(9063):1479-80. PubMed ID: 9164345
    [No Abstract]   [Full Text] [Related]  

  • 58. CGS 26529: the biological profile of a novel, orally active 5-lipoxygenase inhibitor with an extended duration of action.
    Kimble E; Kowalski T; Peters P; Lee W; Koehler J; Raychaudhuri A; Chertock H; Blancuzzi V; van Duzer J
    Inflamm Res; 1995 Aug; 44 Suppl 2():S147-8. PubMed ID: 8548371
    [No Abstract]   [Full Text] [Related]  

  • 59. Heteroarylmethoxyphenylalkoxyiminoalkylcarboxylic acids as leukotriene biosynthesis inhibitors.
    Kolasa T; Gunn DE; Bhatia P; Woods KW; Gane T; Stewart AO; Bouska JB; Harris RR; Hulkower KI; Malo PE; Bell RL; Carter GW; Brooks CD
    J Med Chem; 2000 Feb; 43(4):690-705. PubMed ID: 10691695
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Aqueous stability of SB 210661: kinetics and primary degradation mechanisms of an N-hydroxyurea-containing 5-lipoxygenase inhibitor.
    McLoughlin M; Kearney AS; Palepu NR
    J Pharm Pharmacol; 1998 Feb; 50(2):127-32. PubMed ID: 9530978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.